期刊
GENETICS IN MEDICINE
卷 14, 期 7, 页码 656-662出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/gim.2012.3
关键词
EGFR testing; evidence-based decision making; genomic testing; Lynch syndrome; Oncotype DX; stakeholder engagement
资金
- National Cancer Institute (NCI)
- CANCER-GEN (Comparative Effectiveness Research in Cancer Genomics) through the American Recovery and Reinvestment Act by the NCI, National Institutes of Health [RC2CA138570]
Purpose: Insufficient evidence on the net benefits and harms of genomic tests in real-world settings is a translational barrier for genomic medicine. Understanding stakeholders' assessment of the current evidence base for clinical practice and coverage decisions should be a critical step in influencing research, policy, and practice. Methods: Twenty-two stakeholders participated in a workshop exploring the evidence of genomic tests for clinical and coverage decision making. Stakeholders completed a survey prior to and during the meeting. They also discussed if they would recommend for or against current clinical use of each test. Results: At baseline, the level of confidence in the clinical validity and clinical utility of each test varied, although the group expressed greater confidence for epidermal growth factor receptor mutation and Lynch syndrome testing than for Oncotype DX. Following the discussion, survey results reflected even less confidence for Oncotype DX and epidermal growth factor receptor mutation testing, but not for Lynch syndrome testing. The majority of stakeholders would consider clinical use for all three tests, but under the conditions of additional research or a shared clinical decision-making approach. Conclusion: Stakeholder engagement in unbiased settings is necessary to understand various perspectives about evidentiary thresholds in genomic medicine. Participants recommended the use of various methods for evidence generation and synthesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据